6.
Yang W, Yu T, Huang X, Bilotta A, Xu L, Lu Y
. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020; 11(1):4457.
PMC: 7478978.
DOI: 10.1038/s41467-020-18262-6.
View
7.
Jiang Y, Cui W, Zhang Y, Wang T, Zheng X, Li H
. FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models. Front Physiol. 2023; 14:1195441.
PMC: 10465800.
DOI: 10.3389/fphys.2023.1195441.
View
8.
Billing A, Kim Y, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A
. Metabolic Communication by SGLT2 Inhibition. Circulation. 2023; 149(11):860-884.
PMC: 10922673.
DOI: 10.1161/CIRCULATIONAHA.123.065517.
View
9.
Lau W, Vaziri N, Nunes A, Comeau A, Langille M, England W
. The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease. J Pharmacol Exp Ther. 2018; 367(3):452-460.
DOI: 10.1124/jpet.118.251389.
View
10.
McIntyre C, Harrison L, Eldehni M, Jefferies H, Szeto C, John S
. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 6(1):133-41.
PMC: 3022234.
DOI: 10.2215/CJN.04610510.
View
11.
Means Jr R, Krantz S
. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood. 1991; 78(10):2564-7.
View
12.
Steenbeke M, Valkenburg S, Gryp T, Van Biesen W, Delanghe J, Speeckaert M
. Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease. Toxins (Basel). 2021; 13(11).
PMC: 8625482.
DOI: 10.3390/toxins13110809.
View
13.
Radic J, Basic-Jukic N, Vujicic B, Klaric D, Radulovic G, Jakic M
. Anemia Is Correlated with Malnutrition and Inflammation in Croatian Peritoneal Dialysis Patients: A Multicenter Nationwide Study. Perit Dial Int. 2017; 37(4):472-475.
DOI: 10.3747/pdi.2016.00013.
View
14.
Magnusson M, Magnusson K, Sundqvist T, DENNEBERG T
. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut. 1991; 32(7):754-9.
PMC: 1378990.
DOI: 10.1136/gut.32.7.754.
View
15.
Bhalodi A, van Engelen T, Virk H, Wiersinga W
. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother. 2019; 74(Suppl 1):i6-i15.
PMC: 6382031.
DOI: 10.1093/jac/dky530.
View
16.
Borges N, Barros A, Nakao L, Dolenga C, Fouque D, Mafra D
. Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease. J Ren Nutr. 2016; 26(6):396-400.
DOI: 10.1053/j.jrn.2016.07.005.
View
17.
Kelly C, Zheng L, Campbell E, Saeedi B, Scholz C, Bayless A
. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015; 17(5):662-71.
PMC: 4433427.
DOI: 10.1016/j.chom.2015.03.005.
View
18.
Adelibieke Y, Shimizu H, Saito S, Mironova R, Niwa T
. Indoxyl sulfate counteracts endothelial effects of erythropoietin through suppression of Akt phosphorylation. Circ J. 2013; 77(5):1326-36.
DOI: 10.1253/circj.cj-12-0884.
View
19.
Zhu Y, Tang Y, He H, Hu P, Sun W, Jin M
. Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia. Front Cell Infect Microbiol. 2022; 12:919352.
PMC: 9355670.
DOI: 10.3389/fcimb.2022.919352.
View
20.
Weir M
. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. Am J Nephrol. 2021; 52(6):450-466.
DOI: 10.1159/000516901.
View